HER2-Positive Breast Cancer

In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS

In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS

By

In this study presented at SABCS 2016, investigators determined the association between higher TIL levels and overall survival in patients with advanced HER2-positive breast cancer treated with docetaxel plus trastuzumab in combination with pertuzumab or placebo.

Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab

Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab

By

Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.

Trastuzumab Biosimilar Comparable the Monoclonal Antibody for Advanced HER2+ Breast Cancer

By

MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

By

Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.

New Drug Combination Before Surgery May Improve Outcomes for Advanced HER2+ Breast Cancer

New Drug Combination Before Surgery May Improve Outcomes for Advanced HER2+ Breast Cancer

By

Combining trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab for patients with HER2-positive invasive breast cancer.

Presurgical Treatment in HER2-positive Breast Cancer Achieves Significant Reduction in Disease

By

Treatment with lapatinib and trastuzumab before surgery and chemotherapy led to significant shrinkage or disappearance of the tumors in approximately 25% of women with HER2-positive breast cancer.

Cell Growth Inhibitor Overcomes Therapy Resistance and Delays Tumor Recurrence in Breast Cancer

By

Cyclin D1/CDK4 inhibitor treatment overcame resistance to targeted therapy in transgenic mouse models, cell cultures, and human tissue samples of HER2-positive breast cancer.

Single-dose Trastuzumab Kick Starts Immune Response in Some Breast Cancers

By

Women with the HER2-enriched type of HER2-positive breast cancer had the highest rate of immune response to treatment with trastuzumab, with a significant increase after just 1 dose of the drug.

Young patients with HER2+ breast cancer and no family history have low risk of carrying high risk genes

By

A recent study examined genetic susceptibility in younger patients diagnosed with HER2+ breast cancer.

New mechanism of acquired resistance to breast cancer drugs discovered

By

Researchers have discovered that ERBB4 (also known as HER4) is a driver protein in ERBB2-positive tumors that have developed resistance to first- or second-line treatments.

Combination therapy can reduce chance of recurrence from small HER2+ breast tumors

By

Women with stage 1 HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were unlikely to suffer cancer recurrence within 3 years of treatment.

Trastuzumab improves long-term survival of HER2-positive breast cancer patients

By

Trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients, according to a large national study.

Pertuzumab adds survival benefit for HER2-positive breast cancer

Pertuzumab adds survival benefit for HER2-positive breast cancer

By

Patients with HER2-positive breast cancer that has metastasized demonstrate longer survival outcomes if treated with a combination of pertuzumab, trastuzumab, and chemotherapy.

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancer

By

The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.

ESMO: Herceptin may be best option for HER2+ breast cancer treatment

ESMO: Herceptin may be best option for HER2+ breast cancer treatment

Drug should remain standard of care for HER2-positive tumors, according to new research.

Novel immunotherapy vaccine decreases recurrence of HER2-positive breast cancer

Novel immunotherapy vaccine decreases recurrence of HER2-positive breast cancer

By

A new immunotherapy vaccine candidate for breast cancer shows promise, having reduced recurrence rate by more than fifty percent.

Molecular imaging visualizes novel way to knock down breast cancer

By

A recent innovation in breast cancer biomarkers seeks to visualize the HER3 receptor, which could mean more comprehensive breast cancer imaging and potential treatments.

Invasive recurrence risk explored for HER2+ breast cancer

Invasive recurrence risk explored for HER2+ breast cancer

For patients with HER2+ breast cancer, distant invasive recurrence is low for T1a tumors and is higher for T1b tumors.

Powerful new way to treat HER2-positive breast cancer validated

Powerful new way to treat HER2-positive breast cancer validated

By

HER2-positive breast cancer typically develops resistance to Herceptin within several years. researchers have found a means of inhibiting another protein whose expression is also upregulated in HER2-positive breast cancer.

ASCO releases advanced HER2+ breast cancer guidelines

ASCO releases advanced HER2+ breast cancer guidelines

The American Society for Clinical Oncology (ASCO) has issued recommendations for the treatment of HER2-positive advanced breast cancer and advanced HER2-positive breast cancer with brain metastases.

New approach may overcome breast cancer resistance to HER2-targeted therapies

New approach may overcome breast cancer resistance to HER2-targeted therapies

By

Resistance to a combination of HER2-targeted therapies, trastuzumab and lapatinib, was associated with elevated activation of a group of proteins called fibroblast growth factor receptors, which are the target of a number of drugs under development.

Subtypes of HER2-positive breast cancer with varying sensitivities identified

By

Research has not only shown that HER2-positive breast cancer can be classified into four different subtypes, but has also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.

Trastuzumab benefit predicted by high levels of immune cells in breast cancer tumors

By

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. These results were presented at the 2013 San Antonio Breast Cancer Symposium.

Highly effective treatment options identified for HER2-positive breast cancer

By

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer.

Exercise protects against aggressive breast cancer in black women

By

A nearly 20-year observational study involving more than 44,700 black women nationwide found that regular vigorous exercise offers significant protection against development of an aggressive subtype of breast cancer.

PIK3CA gene mutations make some breast cancers resistant to treatment

By

Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene. These results were presented at the 2013 San Antonio Breast Cancer Symposium.

SABCS: Dual HER2 blockade in breast cancer examined

SABCS: Dual HER2 blockade in breast cancer examined

For human epidermal growth factor receptor 2 (HER2)-positive tumors, the combination of lapatinib and trastuzumab is better than either therapy alone, according to a study.

Concurrent therapy unnecessary to achieve high pathologic remission in breast cancer

By

Giving trastuzumab and anthracyclines concurrently is not necessary to achieve a high rate of complete pathologic remission in HER2-positive breast cancer. The results of a recent phase III clinical trial show that administering the treatments sequentially is equally effective.

ASCO/CAP update advice on HER2 testing in breast cancer

By

All persons with invasive breast cancer (early stage or recurrence) should undergo testing for human epidermal growth factor receptor 2 (HER2), and at least one tumor sample should be tested for either HER2 protein expression or HER2 gene amplification.

A roundup of FDA oncology news from September 2013

By

The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs